Advice
following a full submission
epoetin theta (Eporatio) is accepted for use within NHS Scotland.
Licensed indication under review: the treatment of symptomatic anaemia associated with chronic renal failure in adult patients.
Epoetin theta demonstrated non-inferiority to another erythropoietin analogue in maintaining stable haemoglobin levels in renal failure associated anaemia both in patients not yet receiving dialysis (subcutaneous route) and in those receiving haemodialysis (intravenous route).
The British National Formulary advises that it is good practice to prescribe biological medicinal products by brand name.
Other erythropoietin stimulating agents are available at lower cost.
Download detailed advice97KB (PDF)
Medicine details
- Medicine name:
- epoetin theta (Eporatio)
- SMC ID:
- 620/10
- Indication:
- For the treatment of symptomatic anaemia associated with chronic renal failure in adult patients and the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
- Pharmaceutical company
- Ratiopharm UK
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 July 2010